Researchers at UT Arlington have discovered a key enzyme, IDO1, that when blocked, helps immune cells regain their ability to properly process cholesterol—something that breaks down during ...

Shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) advanced 2.4% after the company announced that the U.S. Food and Drug ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.

Unlike β-blockers, ivabradine does not modify myocardial contractility and intracardiac conduction, even in patients with heart failure with reduced ejection fraction. 183 In 2015, ivabradine was ...

The pathophysiology of heart failure is complex, but mitochondrial dysfunction is an emerging therapeutic target to improve cardiac function. In this Consensus Statement, insights into the ...

Novo Nordisk (($DE:NOVA)) announced an update on their ongoing clinical study. Novo Nordisk has recently completed a clinical study titled ...

Studies of the epidemiology of heart failure in the general population can inform assessments of disease burden, research, public health policy and health system care delivery. We performed a ...

Despite the benefits of proven therapy for heart failure, mortality remains high, with approximately 50% of patients dead at 5 years. [49] Although ACE inhibitors decrease mortality, they ...

Many of the compensatory biochemical mechanisms activated during early heart failure, such as neurohormonal activation and cytokine and growth-factor upregulation, induce myocellular hypertrophy ...

Experimental drug Obicetrapib reduces LDL cholesterol and hard-to-treat lipoprotein(a) levels in heart disease patients, potentially providing a new tool against heart disease.

GPs can start treatment with certain heart failure drugs that previously had to be initiated by a specialist, NICE has said in updated guidance. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and ...

A Danish study published in The BMJ last year found that SGLT-2 inhibitor use was associated with a 25% lower risk of all cause mortality in patients with HFrEF.2 During follow-up 374 deaths occurred ...